CHICAGO, IL -- February 26, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, showcased its new Dynamic Mechanical Analyzer (DMA) at PITTCON® 2007, Booth 843.  The DMA 8000 is the cornerstone of the next generation of PerkinElmer thermal analysis instrumentation and was part of the acquisition of specific DMA technologies from UK-based Triton Technology Ltd. in December 2006.  Scientists in the polymers, composites, pharmaceuticals and food industries can utilize this powerful technology for a wide range of diverse applications ranging from simple quality control to advanced research. 

“PerkinElmer has a long tradition of offering high-quality products and services to all of its customers,” said Mike DiVito, Thermal Analysis business unit manager, PerkinElmer Life and Analytical Sciences.  “We recognize that ease-of-use, flexibility and maximum uptime are critical to our customers.  The DMA 8000 delivers these key attributes and exemplifies PerkinElmer’s continuing commitment to enhance our thermal offerings.”   

The DMA 8000 includes a number of features that will enable scientists to analyze samples more easily, quickly and with greater uptime than other offerings on the market. For unparalleled flexibility, the DMA 8000 has a rotating analysis head, which can be oriented through a full 180 degrees for ease of sample mounting and changing. Its lightweight analytical train is designed for high stiffness, yielding exceptional performance.  The instrumentation has the ability to cool rapidly with minimal liquid nitrogen consumption.  The DMA 8000 also offers precise humidity and temperature control as a sample’s properties are studied, along with an integrated fluid bath for immersion of a sample during testing.

For more information about the DMA 8000, visit www.perkinelmer.com/dma8000.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.